Literature DB >> 28560411

CpG methylation patterns are associated with gene expression variation in osteosarcoma.

Qiang Wang1.   

Abstract

Osteosarcoma is a common malignant tumor in childhood and adolescence (nearly 5% of all cases of cancer in children), as well as a type of tumor with poor prognosis. However, the pathogenesis and molecular mechanisms of osteosarcoma remains to be elucidated. The aim of the current study was to determine the association between methylation and gene expression changes in osteosarcoma cell line. Microarray data were obtained from the Gene Expression Omnibus database (GSE36004). Genome‑wide methylation status was determined in 19 different osteosarcoma cell lines and 6 normal controls. Differentially expressed genes (DEGs) were identified from cancer cells with genefilter package in R and differentially methylated sites were screened with CpGassoc package in R. Integrated gene expression with methylation profiles, genes differentially expressed and methylated, were obtained, and transcriptional regulatory network construction was performed. Functional annotation was performed for genes in the network using the DAVID online tool. Following integrated analysis, a total of 75 methylated sites were demonstrated to be localized at a transcription factor binding region. These sites may be bound by 83 transcription factors which will then alter the expression of 75 downstream DEGs. In the regulatory network, seizure related 6 homolog like 2 (SEZ6L2) had the highest degree of upregulation and was demonstrated to be regulated by 12 transcription factors. Furthermore, kin of IRRE like (KIRREL), centrosomal protein 72 (CEP72) and cyclin‑dependent kinase 4 (CDK4) were also regulated by more than three transcription factors. Functional annotation revealed that the upregulated genes were primarily involved in the cell cycle pathway. Several differentially methylated sites were associated with upregulation of SEZ6L2, KIRREL, CEP72 and CDK4 and may have an important role in the pathogenesis of osteosarcomas through promotion of cell proliferation and metastasis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28560411     DOI: 10.3892/mmr.2017.6635

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

Review 1.  Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer.

Authors:  Michela Coan; Gian Luca Rampioni Vinciguerra; Laura Cesaratto; Emanuela Gardenal; Riccardo Bianchet; Erik Dassi; Andrea Vecchione; Gustavo Baldassarre; Riccardo Spizzo; Milena Sabrina Nicoloso
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

2.  Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells.

Authors:  Songsong Teng; Chunhui Ma; Yinxian Yu; Chengqing Yi
Journal:  Biosci Rep       Date:  2019-05-14       Impact factor: 3.840

3.  Overexpression of Kin of IRRE-Like Protein 1 (KIRREL) in Gastric Cancer and Its Clinical Prognostic Significance.

Authors:  Ming-Jun Zhang; Yan-Yan Hong; Na Li
Journal:  Med Sci Monit       Date:  2018-05-02

4.  Upregulated Seizure-Related 6 Homolog-Like 2 Is a Prognostic Predictor of Hepatocellular Carcinoma.

Authors:  Linhe Wang; Xiangchao Ling; Caihui Zhu; Zhiheng Zhang; Ziming Wang; Shanzhou Huang; Yunhua Tang; Shujiao He; Zhiyong Guo; Xiaoshun He
Journal:  Dis Markers       Date:  2020-02-13       Impact factor: 3.434

Review 5.  Biology and pathogenesis of human osteosarcoma.

Authors:  Judson Welber Veríssimo de Azevedo; Thales Allyrio Araújo de Medeiros Fernandes; José Veríssimo Fernandes; Jenner Chrystian Veríssimo de Azevedo; Daniel Carlos Ferreira Lanza; Christiane Medeiros Bezerra; Vânia Sousa Andrade; Josélio Maria Galvão de Araújo; José Veríssimo Fernandes
Journal:  Oncol Lett       Date:  2019-12-18       Impact factor: 2.967

6.  Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma.

Authors:  Ziming Wang; Jiaming Lai; Lijian Liang; Xiaoyu Yin; Qian Wang; Quanyong Cheng; Chaoxu Zheng
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.